DOP2019000291A - Método para preparar intermedio de derivado de 4-metoxipirrol - Google Patents
Método para preparar intermedio de derivado de 4-metoxipirrolInfo
- Publication number
- DOP2019000291A DOP2019000291A DO2019000291A DO2019000291A DOP2019000291A DO P2019000291 A DOP2019000291 A DO P2019000291A DO 2019000291 A DO2019000291 A DO 2019000291A DO 2019000291 A DO2019000291 A DO 2019000291A DO P2019000291 A DOP2019000291 A DO P2019000291A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- preparing
- metoxypirrol
- derivative intermediate
- present
- methoxypyrrole
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170078745A KR102233455B1 (ko) | 2017-06-21 | 2017-06-21 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| PCT/KR2018/006989 WO2018236153A1 (en) | 2017-06-21 | 2018-06-21 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF 4-METHOXYPYRROLE DERIVATIVE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000291A true DOP2019000291A (es) | 2019-12-15 |
Family
ID=64735783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000291A DOP2019000291A (es) | 2017-06-21 | 2019-11-14 | Método para preparar intermedio de derivado de 4-metoxipirrol |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11345660B2 (ko) |
| EP (1) | EP3642181B1 (ko) |
| JP (1) | JP6799178B2 (ko) |
| KR (1) | KR102233455B1 (ko) |
| CN (1) | CN110582482B (ko) |
| AU (1) | AU2018288933B2 (ko) |
| BR (1) | BR112019027323A2 (ko) |
| CA (1) | CA3061713C (ko) |
| CL (1) | CL2019003450A1 (ko) |
| CO (1) | CO2019012689A2 (ko) |
| DO (1) | DOP2019000291A (ko) |
| EC (1) | ECSP19081847A (ko) |
| ES (1) | ES2901701T3 (ko) |
| HR (1) | HRP20211819T1 (ko) |
| HU (1) | HUE057666T2 (ko) |
| JO (1) | JOP20190265B1 (ko) |
| MA (1) | MA49472B1 (ko) |
| MY (1) | MY188800A (ko) |
| NZ (1) | NZ758770A (ko) |
| PE (1) | PE20210151A1 (ko) |
| PH (1) | PH12019502865A1 (ko) |
| PL (1) | PL3642181T3 (ko) |
| PT (1) | PT3642181T (ko) |
| RS (1) | RS62564B1 (ko) |
| RU (1) | RU2737470C1 (ko) |
| SA (1) | SA519410407B1 (ko) |
| SG (1) | SG11201911164WA (ko) |
| SI (1) | SI3642181T1 (ko) |
| TN (1) | TN2019000301A1 (ko) |
| WO (1) | WO2018236153A1 (ko) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| US10789690B2 (en) * | 2018-03-07 | 2020-09-29 | Adobe Inc. | Masking non-public content |
| CN109867617A (zh) * | 2019-04-03 | 2019-06-11 | 南京格亚医药科技有限公司 | 一种4-甲氧基吡咯中间体的制备方法 |
| CN112094219B (zh) * | 2020-09-10 | 2022-08-05 | 广东莱佛士制药技术有限公司 | 一种制备钾离子竞争性阻滞剂中间体的方法 |
| CN117326961B (zh) * | 2023-09-27 | 2024-05-03 | 安徽峆一药业股份有限公司 | 一种非苏拉赞中间体的绿色合成方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622948A (en) | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| EP2336107B1 (en) | 2004-09-30 | 2015-09-23 | Takeda Pharmaceutical Company Limited | Proton pump inhibitors |
| PL1919865T3 (pl) | 2005-08-30 | 2011-09-30 | Takeda Pharmaceuticals Co | 1-heterocyklilosulfonylo, 2-aminometylo, 5-(hetero-) arylo podstawione pochodne 1-h-pirolu jako kwasowe inhibitory wydzielania |
| KR101174191B1 (ko) | 2007-02-02 | 2012-08-14 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린 |
| CN102088855A (zh) * | 2008-05-08 | 2011-06-08 | 百时美施贵宝公司 | 2-芳基甘氨酰胺衍生物 |
| US8895558B2 (en) * | 2008-10-02 | 2014-11-25 | Green Cross Corporation | Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders |
| KR101613245B1 (ko) * | 2015-04-27 | 2016-04-18 | 주식회사 대웅제약 | 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물 |
| WO2017164575A1 (en) | 2016-03-25 | 2017-09-28 | Daewoong Pharmaceutical Co.,Ltd. | Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n- methylmethanamine |
| KR20170113040A (ko) * | 2016-03-25 | 2017-10-12 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민의 신규한 산부가염 |
| KR102081920B1 (ko) | 2016-03-25 | 2020-02-26 | 주식회사 대웅제약 | 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형 |
| KR102233456B1 (ko) * | 2017-05-31 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102233455B1 (ko) * | 2017-06-21 | 2021-03-29 | 주식회사 대웅제약 | 4-메톡시피롤 유도체의 중간체 제조 방법 |
| KR102126576B1 (ko) * | 2018-09-19 | 2020-06-24 | 주식회사 대웅제약 | 4-메톡시 피롤 유도체의 제조 방법 |
-
2017
- 2017-06-21 KR KR1020170078745A patent/KR102233455B1/ko active IP Right Grant
-
2018
- 2018-06-21 MA MA49472A patent/MA49472B1/fr unknown
- 2018-06-21 HU HUE18821303A patent/HUE057666T2/hu unknown
- 2018-06-21 RU RU2019135250A patent/RU2737470C1/ru active
- 2018-06-21 EP EP18821303.7A patent/EP3642181B1/en active Active
- 2018-06-21 JO JOP/2019/0265A patent/JOP20190265B1/ar active
- 2018-06-21 RS RS20211408A patent/RS62564B1/sr unknown
- 2018-06-21 CA CA3061713A patent/CA3061713C/en active Active
- 2018-06-21 SG SG11201911164WA patent/SG11201911164WA/en unknown
- 2018-06-21 PL PL18821303T patent/PL3642181T3/pl unknown
- 2018-06-21 US US16/608,924 patent/US11345660B2/en active Active
- 2018-06-21 ES ES18821303T patent/ES2901701T3/es active Active
- 2018-06-21 PT PT188213037T patent/PT3642181T/pt unknown
- 2018-06-21 NZ NZ758770A patent/NZ758770A/en unknown
- 2018-06-21 AU AU2018288933A patent/AU2018288933B2/en active Active
- 2018-06-21 MY MYPI2019006395A patent/MY188800A/en unknown
- 2018-06-21 WO PCT/KR2018/006989 patent/WO2018236153A1/en unknown
- 2018-06-21 HR HRP20211819TT patent/HRP20211819T1/hr unknown
- 2018-06-21 CN CN201880029597.9A patent/CN110582482B/zh active Active
- 2018-06-21 JP JP2019563427A patent/JP6799178B2/ja active Active
- 2018-06-21 BR BR112019027323-9A patent/BR112019027323A2/pt unknown
- 2018-06-21 SI SI201830482T patent/SI3642181T1/sl unknown
- 2018-06-21 PE PE2019002402A patent/PE20210151A1/es unknown
- 2018-06-21 TN TNP/2019/000301A patent/TN2019000301A1/en unknown
-
2019
- 2019-10-29 SA SA519410407A patent/SA519410407B1/ar unknown
- 2019-11-14 CO CONC2019/0012689A patent/CO2019012689A2/es unknown
- 2019-11-14 DO DO2019000291A patent/DOP2019000291A/es unknown
- 2019-11-15 EC ECSENADI201981847A patent/ECSP19081847A/es unknown
- 2019-11-26 CL CL2019003450A patent/CL2019003450A1/es unknown
- 2019-12-18 PH PH12019502865A patent/PH12019502865A1/en unknown
-
2022
- 2022-04-29 US US17/732,804 patent/US20220259146A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19081847A (es) | Método para preparar intermedio de derivado de 4-metoxipirrol | |
| DOP2019000292A (es) | Método para preparar intermedio de derivado de 4-metoxipirrol | |
| PH12018500093A1 (en) | Process for the production of cannabidiol and delta-9-tetrahydrocannabinol | |
| CL2019002793A1 (es) | Composición para producir tagatosa y procedimiento de producción de tagatosa usando la misma. | |
| BR112017022488A2 (pt) | produção microbiana de terpenoides | |
| BR112015031233A2 (pt) | métodos de produção de derivados de ácidos graxos omega-hidroxilados | |
| CL2018003602A1 (es) | Proceso para preparar almidón hidrolizado con contenido de azúcar reducido. | |
| MX2020004869A (es) | Metodo para preparar derivado de benzofurano. | |
| EA201690696A1 (ru) | Способ получения адамантанамидов | |
| BR112016025024A2 (pt) | ?processo para preparar compostos ceto, e, uso de farnesil acetona? | |
| WO2015120111A3 (en) | Expedient synthesis of sitagliptin | |
| BR112014014762A2 (ko) | A method of producing a cysteine or derivatives thereof using the novel phosphine O- porcelain seolpeu Hyde Lila Ajay | |
| AR098879A1 (es) | Síntesis de ent-progesterona y sus productos intermedios | |
| MX2018010128A (es) | Toxina nueva y metodo de preparacion de un intermediario de la misma. | |
| WO2015114518A3 (en) | Procedure for the preparation of abiraterone acetate and intermediates thereof | |
| BR112018004854A8 (pt) | Processo para a produção de hidrolisado dessalinizado de biomassa, hidrolisado dessalinizado preparado pelo dito processo e uso do dito hidrolisado dessalinizado como um meio de fermentação | |
| BR112015026740A2 (pt) | método para sintetizar derivados de furano, e, método para preparar derivados de furano | |
| BR112017004368A2 (ko) | L- lysine production method using L- lysine-producing ability and improved microbial them | |
| BR112017008663A2 (pt) | método para a produção de álcool | |
| BR112022007354A2 (pt) | Processo para síntese de picolinamidas | |
| PL407240A1 (pl) | Sposób wytwarzania (2S,4S)-cis-flawan-4-olu | |
| CA2935504C (en) | Synthesis method of 9-allylcamptothecin derivatives | |
| BR112017019116A2 (pt) | método para preparar composto de sulfonamida de alta pureza e intermediário do composto de sulfonamida | |
| TH168117A (th) | จุลชีพที่รีคอมบิแนนท์ที่มีการแสดงออกของอะเวอร์เมคตินอะนาล็อก และการใช้ของพวกมัน |